Synopsis
Distinguish a first clinical demyelinating event from incidental MRI appearances, quantify future multiple-sclerosis risk without deterministic counselling, and arrange specialist surveillance or treatment according to evolving criteria.
- Clinically isolated syndrome is a first objective neurological episode caused by central inflammatory demyelination, lasting at least 24 hours, in a person not yet shown to meet full multiple-sclerosis criteria.
- Typical clinically isolated syndromes are unilateral optic neuritis, partial transverse myelitis, a brainstem event or a cerebellar syndrome; vague dizziness, fatigue or paraesthesia without objective localisation is less specific.
- Some first events already meet contemporary multiple-sclerosis criteria through MRI dissemination and cerebrospinal-fluid biomarkers, so clinically isolated syndrome is not a mandatory prolonged waiting stage.
- Radiologically isolated syndrome describes MRI lesions highly characteristic of demyelination discovered in someone without historical or current clinical manifestations attributable to them.
- Migraine, age-related small-vessel disease, vasculitis, previous infection and genetic white-matter disorders can mimic radiological isolation; lesion shape and location must be reviewed by experienced neuroradiology and neurology teams.
- Future clinical-event risk after either syndrome rises with younger age, spinal-cord or infratentorial lesions, gadolinium enhancement, new lesions over time and cerebrospinal-fluid-specific oligoclonal bands.
- Test serum aquaporin-4 and MOG antibodies when optic neuritis or myelitis is severe, bilateral, recurrent, longitudinally extensive or otherwise atypical for ordinary multiple sclerosis.
- High-dose methylprednisolone may accelerate recovery from a functionally significant clinical attack but does not convert an incidental radiological syndrome into a symptomatic relapse.
- Disease-modifying therapy can be appropriate after a high-risk clinical syndrome or when current multiple-sclerosis criteria are met; exact licensing and NHS eligibility require specialist confirmation.
- Selected people with radiologically isolated syndrome can now fulfil the 2024 revised McDonald criteria for multiple sclerosis, but diagnosis does not itself mandate disease-modifying treatment; evidence, licensing, NHS eligibility, risks and patient preference still require specialist review.
Key red flags
Bilateral optic involvement, chiasmal disease, complete myelitis, longitudinally extensive cord signal or area-postrema symptoms suggest aquaporin-4 or MOG-associated disease and need urgent specialist assessment.
Investigation priorities
Assess lesion morphology, distribution, enhancement and evidence of dissemination.
Management branches
A first optic, cord, brainstem or cerebellar syndrome evolves over hours to days.
- Localise with a full neurological and ophthalmic examination, documenting duration, functional impact, previous subtle attacks and vascular, compressive, infectious or systemic clues.
- Arrange urgent imaging for severe cord or brainstem disease and specialist protocol brain and spinal MRI for a stable typical event, adding cerebrospinal fluid when it changes criteria.
- Apply current diagnostic criteria through neurology, communicating whether the outcome is multiple sclerosis, clinically isolated syndrome or unresolved atypical inflammation.
Key medicines
Methylprednisolone for a clinical attackWhen a first demyelinating event is disabling, specialists may use the NICE multiple-sclerosis relapse regimen of 0.5 g orally daily for 5 days or selected intravenous therapy.Exclude infection, review glucose and psychiatric risk, and explain that response neither proves multiple sclerosis nor prevents future conversion; incidental MRI lesions alone are not a steroid indication.
Disease-modifying therapy after CISUse only an agent and schedule licensed, NICE-approved and NHS-commissioned for the person's confirmed diagnosis and risk profile under an MS specialist.Balance infection, malignancy, pregnancy, vaccine, monitoring and rebound risks; the applicable criteria and product licences change, so generic initiation is unsafe.